![](https://medcitynews.com/wp-content/uploads/sites/7/2020/04/Getty-Images-Stress-Anxiety-Aleksei-Morozov-e1602270358743.jpg)
While Sage Therapeutics sees a window for depression drug, market is skeptical
A Sage Therapeutics depression drug that failed a pivotal study in 2019 has positive preliminary results from a new Phase 3 clinical trial, but the data also showed the therapy's effects waned over time. Questions about zuranolone’s durability are relevant to Biogen, which committed $1.5 billion to Sage in large part due to the drug’s potential in multiple psychiatric indications.